Ocuphire Pharma Inc

NASDAQ:OCUP  
2.13
-0.01 (-0.47%)
Products

Ocuphire Announces Positive Topline Results From MIRA-3 Phase 3 FDA Registration Trial For Nyxol

Published: 03/29/2022 11:18 GMT
Ocuphire Pharma Inc (OCUP) - Ocuphire Announces Positive Topline Results From Mira-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis.
Ocuphire Pharma- Meets Primary Endpoint With 58% of Nyxol Treated Returning to Baseline Pupil Diameter at 90 Mins Compared to 6% of Placebo Subjects.
Mira-3 Confirms Prior Mira-2 Phase 3 Registration Trial Showing Substantial Benefit in Accelerating Reversal of Mydriasis.
NDA Filing for Nyxol in Rm Planned for Late 2022.